** Shares of drugmaker Madrigal Pharmaceuticals MDGL.O rise 13.8% to $352.3
** Co reports Q4 sales of $103.3 mln from its fatty liver disease drug Rezdiffra, beating analysts' estimate of $71.95 mln as per data compiled by LSEG
** Two-year data from a late-stage study evaluating Rezdiffra shows it helped significantly reduce liver stiffness in patients with metabolic dysfunction-associated steatohepatitis (MASH)
** Says 51% of patients enrolled in the trial achieved 25% or greater reduction in liver stiffness -MDGL
** Significant reduction of liver stiffness has been associated with reduced progression to end-stage liver disease -MDGL
** MASH is a serious condition that causes excess build up of fat in the liver and causes inflammation and fibrosis, or scarring, of the organ
** Stock has risen 33% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。